Back انسیترلویر Persian Ensitrelvir Italian エンシトレルビル Japanese Энситрелвир Russian เอนซิเทรลเวียร์ Thai Енсітрелвір Ukrainian 恩司特韦 Chinese

Ensitrelvir

Ensitrelvir
Clinical data
Trade namesXocova
Other namesS-217622
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life42–48 hours[2]
Identifiers
  • 1-(2,4,5-Trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC22H17ClF3N9O2
Molar mass531.88 g·mol−1
3D model (JSmol)
  • Cn1cnc(CN2C(=O)N(Cc3cc(F)c(F)cc3F)C(=N\c3cc4cn(C)nc4cc3Cl)\NC2=O)n1
  • InChI=1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)
  • Key:QMPBBNUOBOFBFS-UHFFFAOYSA-N
Xocova in a Japanese blister pack

Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19.[3][4][5][6] It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor.[7][8] It is taken by mouth.[9][10][11]

The most common adverse events include transient decreases in high-density lipoprotein and increased blood triglycerides.[9]

  1. ^ Cite error: The named reference NHK WORLD 2024 was invoked but never defined (see the help page).
  2. ^ Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R (October 2022). "Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults". Antimicrobial Agents and Chemotherapy. 66 (10): e0063222. doi:10.1128/aac.00632-22. PMC 9578392. PMID 36094202.
  3. ^ McCarthy MW (December 2022). "Ensitrelvir as a potential treatment for COVID-19". Expert Opinion on Pharmacotherapy. 23 (18): 1995–1998. doi:10.1080/14656566.2022.2146493. PMID 36350029. S2CID 253418404.
  4. ^ Fujikawa M (22 November 2022). "Japan Approves First Homegrown Covid-19 Antiviral Pill". The Wall Street Journal. Retrieved 28 November 2022.
  5. ^ "Shionogi's Covid antiviral lands first approval in Japan's new emergency approval pathway". Endpoints News. 22 November 2022. Retrieved 28 November 2022.
  6. ^ "Xocova: Powerful New Japanese Pill for Coronavirus Treatment". BioPharma News. February 2022.
  7. ^ Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. (May 2022). "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19". Journal of Medicinal Chemistry. 65 (9): 6499–6512. doi:10.1021/acs.jmedchem.2c00117. PMC 8982737. PMID 35352927.
  8. ^ "Shionogi presents positive Ph II/III results for COVID-19 antiviral S-217622". thepharmaletter.com. 31 January 2022.
  9. ^ a b "Xocova (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System". Shionogi (Press release). 22 November 2022. Retrieved 28 November 2022.
  10. ^ "Shionogi's new COVID pill appears to ease omicron symptoms". Nikkei Asia. 21 December 2021.
  11. ^ Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. (IASO study team) (May 2022). "Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2". Nature. 607 (7917): 119–127. Bibcode:2022Natur.607..119U. doi:10.1038/s41586-022-04856-1. PMC 10579982. PMID 35576972. S2CID 248833104.
From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Nelliwinne